{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:08:41Z","timestamp":1789715321208,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T00:00:00Z","timestamp":1446768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1245\/s10434-015-4965-6","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T15:11:18Z","timestamp":1446822678000},"page":"1496-1500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment"],"prefix":"10.1245","volume":"23","author":[{"given":"Sean","family":"Judge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Loggie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,6]]},"reference":[{"key":"4965_CR1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/10408440903044928","volume":"39","author":"B Price","year":"2009","unstructured":"Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576\u201388.","journal-title":"Crit Rev Toxicol."},{"key":"4965_CR2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/annonc\/mdp307","volume":"21","author":"VdeP Manzini","year":"2010","unstructured":"Manzini Vde P, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21:348\u201353.","journal-title":"Ann Oncol."},{"key":"4965_CR3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1055-3207(03)00045-0","volume":"12","author":"PH Sugarbaker","year":"2003","unstructured":"Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am. 2003;12:605\u201321, xi","journal-title":"Surg Oncol Clin North Am."},{"key":"4965_CR4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jso.21787","volume":"103","author":"D Baratti","year":"2011","unstructured":"Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011;103:822\u201331.","journal-title":"J Surg Oncol."},{"key":"4965_CR5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1245\/s10434-013-3261-6","volume":"21","author":"K Lohani","year":"2014","unstructured":"Lohani K, Shetty S, Sharma P, Govindarajan V, Thomas P, Loggie B. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment. Ann Surg Oncol. 2014;21:1441\u20137.","journal-title":"Ann Surg Oncol."},{"key":"4965_CR6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1593\/neo.09284","volume":"11","author":"G Srikrishna","year":"2009","unstructured":"Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 2009;11:615\u201328.","journal-title":"Neoplasia."},{"key":"4965_CR7","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1038\/sj.onc.1206462","volume":"22","author":"T Ramirez-Montagut","year":"2003","unstructured":"Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene. 2003;22:3180\u20137.","journal-title":"Oncogene."},{"key":"4965_CR8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-065X.2009.00771.x","volume":"229","author":"G Driessens","year":"2009","unstructured":"Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009;229:126\u201344.","journal-title":"Immunol Rev."},{"key":"4965_CR9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298\u2013306.","journal-title":"Nat Rev Cancer."},{"key":"4965_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0002-9440(10)64164-8","volume":"161","author":"S Huang","year":"2002","unstructured":"Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161:125\u201334.","journal-title":"Am J Pathol."},{"key":"4965_CR11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1165\/ajrcmb.12.6.7766422","volume":"12","author":"VB Antony","year":"1995","unstructured":"Antony VB, Hott JW, Kunkel SL, Godbey SW, Burdick MD, Strieter RM. Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. Am J Respir Cell Mol Biol. 1995;12:581\u20138.","journal-title":"Am J Respir Cell Mol Biol."},{"key":"4965_CR12","first-page":"367","volume":"59","author":"G Galffy","year":"1999","unstructured":"Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 1999;59:367\u201371.","journal-title":"Cancer Res."},{"key":"4965_CR13","first-page":"187","volume":"11","author":"G Galffy","year":"1999","unstructured":"Galffy G, Mohammed KA, Nasreen N, Ward MJ, Antony VB. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. Oncol Res. 1999;11:187\u201394.","journal-title":"Oncol Res."},{"key":"4965_CR14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/1096-9896(200011)192:3<413::AID-PATH738>3.0.CO;2-1","volume":"192","author":"M Kunz","year":"2000","unstructured":"Kunz M, Goebeler M, Brocker EB, Gillitzer R. IL-8 mRNA expression in primary malignant melanoma mRNA in situ hybridization: sensitivity, specificity, and evaluation of data. J Pathol. 2000;192:413\u20135.","journal-title":"J Pathol."},{"key":"4965_CR15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00008390-199506000-00006","volume":"5","author":"C Scheibenbogen","year":"1995","unstructured":"Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res. 1995;5:179\u201381.","journal-title":"Melanoma Res."},{"key":"4965_CR16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF02361238","volume":"29","author":"T Ueda","year":"1994","unstructured":"Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol. 1994;29:423\u20139.","journal-title":"J Gastroenterol."},{"issue":"16 Pt 1","key":"4965_CR17","first-page":"5996","volume":"9","author":"Y Ren","year":"2003","unstructured":"Ren Y, Poon RT, Tsui HT, et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res. 2003;9(16 Pt 1):5996\u20136001.","journal-title":"Clin Cancer Res."},{"key":"4965_CR18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/2278-0513.125802","volume":"3","author":"KC Chadha","year":"2014","unstructured":"Chadha KC, Miller A, Nair BB, Schwartz SA, Trump DL, Underwood W. New serum biomarkers for prostate cancer diagnosis. Clin Cancer Investig J. 2014;3:72\u20139.","journal-title":"Clin Cancer Investig J."},{"key":"4965_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","volume":"22","author":"MF Neurath","year":"2011","unstructured":"Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation, and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011;22:83\u20139.","journal-title":"Cytokine Growth Factor Rev."},{"key":"4965_CR20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ijc.2910510220","volume":"51","author":"D Schmitter","year":"1992","unstructured":"Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer. 1992;51:296\u2013301.","journal-title":"Int J Cancer."},{"key":"4965_CR21","doi-asserted-by":"crossref","first-page":"17111","DOI":"10.1073\/pnas.1108121108","volume":"108","author":"C Meyer","year":"2011","unstructured":"Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A. 2011;108:17111\u20136.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"4965_CR22","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00262-011-1029-z","volume":"60","author":"BL Mundy-Bosse","year":"2011","unstructured":"Mundy-Bosse BL, Young GS, Bauer T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011;60:1269\u201379.","journal-title":"Cancer Immunol Immunother."},{"key":"4965_CR23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","volume":"1","author":"P Chomarat","year":"2000","unstructured":"Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1:510\u201314.","journal-title":"Nat Immunol."},{"key":"4965_CR24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1471-4906(02)00009-1","volume":"24","author":"Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM","year":"2003","unstructured":"Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol. 2003;24:36\u201343.","journal-title":"Trends Immunol."},{"key":"4965_CR25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","volume":"193","author":"L Strizzi","year":"2001","unstructured":"Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193:468\u201375.","journal-title":"J Pathol."},{"key":"4965_CR26","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096\u2013103.","journal-title":"Nat Med."},{"key":"4965_CR27","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30:2509\u201315.","journal-title":"J Clin Oncol."},{"key":"4965_CR28","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","volume":"27","author":"JP Hegmans","year":"2006","unstructured":"Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006;27:1086\u201395.","journal-title":"Eur Respir J."},{"key":"4965_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2010.05554.x","volume":"1203","author":"JM Hillegass","year":"2010","unstructured":"Hillegass JM, Shukla A, Lathrop SA, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci. 2010;1203:7\u201314.","journal-title":"Ann N Y Acad Sci."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4965-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-015-4965-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4965-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T07:22:13Z","timestamp":1559632933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-015-4965-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,6]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["4965"],"URL":"https:\/\/doi.org\/10.1245\/s10434-015-4965-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,6]]}}}